Session » SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

Date: Sunday, November 7, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 0867

A Proteomic/Transcriptomic Analysis Associates with Subclinical Vascular Disease in Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 0879

Anti-dsDNA Antibodies Increase Systemic Lupus Erythematosus Cardiovascular Risk Impairing the Immune and Cardiovascular Systems

8:30AM-10:30AM: Abstract Number: 0876

Antibody Response in Patients with Systemic Lupus Erythematosus After a Two-dose Regimen with SARS-CoV-2 Vaccines (Preliminary Results)

8:30AM-10:30AM: Abstract Number: 0877

Association of HCQ Blood Levels with Type 1 and 2 SLE Activity

8:30AM-10:30AM: Abstract Number: 0887

Association of Mycophenolate and Azathioprine Use with Cognitive Function in SLE

8:30AM-10:30AM: Abstract Number: 0889

Association of Subjective Cognitive Report Using PDQ-20 to a Neuropsychological Battery in a Cohort of SLE Patients

8:30AM-10:30AM: Abstract Number: 0857

Association of Telomere Length with Phenotypic Frailty in Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 0860

Associations Between Tricarboxylic Acid Cycle Plasma Metabolites and Fatigue Phenotypes in Black Females with Systemic Lupus Erythematosus: An Untargeted Metabolomics Analysis

8:30AM-10:30AM: Abstract Number: 0855

Asymptomatic Coronary Artery Disease Assessed by Coronary Computed Tomography in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis

8:30AM-10:30AM: Abstract Number: 0870

Blood Brain Barrier Integrity and Brain Imaging Patterns in Patients with SLE

8:30AM-10:30AM: Abstract Number: 0868

Cell-bound Complement Activation Products (CB-CAPs) Predicts Type 1 SLE Activity

8:30AM-10:30AM: Abstract Number: 0866

Characteristics Associated with Poor COVID-19 Outcomes in People with Systemic Lupus Erythematosus (SLE): Data from the COVID-19 Global Rheumatology Alliance (GRA)

8:30AM-10:30AM: Abstract Number: 0873

Clinical and Serological Characteristics of Latin American Patients with Lupus Enteritis: A Case-Control Study

8:30AM-10:30AM: Abstract Number: 0869

Comparison of Two Frailty Definitions in Women with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 0882

COVID-19 Impact Among Patients with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 0890

Depression Is Associated with Frailty in Systemic Lupus Erythematosus Patients: Multicenter Retrospective Analysis Using Systemic Lupus Erythematosus International Collaborating Clinics-Frailty Index

8:30AM-10:30AM: Abstract Number: 0886

Determinants of Accessing Social and News Media and Experiencing Negative Impacts During COVID-19 in an International SLE Sample

8:30AM-10:30AM: Abstract Number: 0888

Disease Flares in Lupus Are Concordant with Ruminococcus Blautia Gnavus Blooms Within Unstable Gut Microbiota Communities

8:30AM-10:30AM: Abstract Number: 0864

Does Obesity Affect Disease Activity Outcomes in Systemic Lupus Erythematosus?

8:30AM-10:30AM: Abstract Number: 0881

Economic Evaluation of Neuropsychiatric (NP) Lupus in an International Inception Cohort Using a Multistate Model Approach

8:30AM-10:30AM: Abstract Number: 0858

Effect of COVID Infection and COVID Vaccination on SLE Activity, Including Antiphospholipid Antibodies

8:30AM-10:30AM: Abstract Number: 0859

Evaluation of the Montreal Cognitive Assessment as a Screening Tool for Cognitive Dysfunction in Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 0884

Genetics of Longitudinal Disease Activity in Adults with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 0880

Health Information Use by SLE Patients Pre and During COVID-19

8:30AM-10:30AM: Abstract Number: 0894

Help-seeking Behaviors and Treatment Preferences for Sleep Problems Among Persons with Lupus

8:30AM-10:30AM: Abstract Number: 0856

Identifying COVID-19 Infection Rates and Outcomes in Patients with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 0895

Insight into Intraindividual Variability Across Neuropsychological Tests and Its Association with Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 0878

Investigating the Neutrophil to Lymphocyte Ratio as a Marker of SLE Disease Activity, Health-Related Quality of Life and Depression

8:30AM-10:30AM: Abstract Number: 0872

Lack of Association Between Cognitive Test Performance and Cognitive Symptoms in Systemic Lupus Erythematosus (SLE)

8:30AM-10:30AM: Abstract Number: 0865

Lupus Low Disease Activity State Attainment Provides Significant Protection Against Mortality: A Multi-National, Longitudinal Observational Study

8:30AM-10:30AM: Abstract Number: 0883

Multimorbidity Burden in Systemic Lupus Erythematosus: A Nationwide Study

8:30AM-10:30AM: Abstract Number: 0862

Prevalence and Risk Factors for Herpes Zoster Reactivation in 1542 Patients with Rheumatic Diseases

8:30AM-10:30AM: Abstract Number: 0891

Quality of Life Assessment in an Indian Inception Cohort (INSPIRE) of SLE Using Lupus QoL Questionnaire

8:30AM-10:30AM: Abstract Number: 0875

Renal Function, Adherence and Low Hydroxychloroquine Dosing Predict HCQ Blood Levels and Lupus Disease Activity

8:30AM-10:30AM: Abstract Number: 0892

Screening for Cognitive Impairment with the Automated Neuropsychological Assessment Metrics in Patients with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 0874

Serum Galectin-9 and CXCL-10 but Not Their Urinary Levels Reflect Lupus Activity

8:30AM-10:30AM: Abstract Number: 0863

Serum Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) and Cardiovascular Risk in Systemic Lupus Erythematosus: A Longitudinal Cohort Study

8:30AM-10:30AM: Abstract Number: 0885

SLE Phenotypes Formed from Machine Learning and Their Associations with Cognitive Impairment

8:30AM-10:30AM: Abstract Number: 0896

Systemic Lupus Erythematosus Disease Flares After SARS-CoV-2 Vaccination

8:30AM-10:30AM: Abstract Number: 0861

Systemic Lupus Erythematosus, a Pilot Study of a New Disease Activity Score

8:30AM-10:30AM: Abstract Number: 0871

The Association of Hydroxychloroquine Dosing with Adverse Cardiovascular Events in Patients with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 0893

Trajectories of Depressive Symptoms in Systemic Lupus Erythematosus over 7 Years

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].